

## 6-Month Progress Report to Cystic Fibrosis Australia -

**Report by:** Stefanie Bader – PhD Candidate Pellegrini Laboratory

**Project Name:** Progressing a novel treatment paradigm to improve management of infections in people with CF

**Date of report:** 16 Jun 2022

### **Research Progress:**

This Fellowship has provided me with an invaluable opportunity to travel to the lab of Prof. Alessandra Bragonzi in Milan. This collaboration combines the expertise of WEHI's Pellegrini lab in the use of cell death inducing compounds to clear infections with the extensive experience of the Bragonzi lab with different cystic fibrosis and *P. aeruginosa* pre-clinical models.

My travel commences end of June when I will start by testing the efficacy of compound A-1331852 (BCL-XL inhibitor) to treat chronic *P.aeruginosa* infection in wild type mice. Over four weeks, I will test different concentrations of compounds, as well as Debio-1143 (SMAC-mimetic). Pending positive results, my visit will be extended for two weeks to trial the most promising drug in a *P. aeruginosa* infection model using cystic fibrosis mice.

Thank you to Cystic Fibrosis Australia for supporting my research through the Ann Maree Bosch Career Fellowship.

**Signed:**

**Date:** 16/06/2022



**Stefanie Bader**